治疗点传染病诊断方面的进展:技术的整合,验证,人工智能和监管监督
1CRO Division, Dicentra, Toronto, ON M4W 3E2, Canada.
Diagnostics (Basel, Switzerland)
|November 27, 2025
概括
护理点 (POC) 传染病诊断正在迅速发展,整合了人工智能和分子放大等技术,用于全球健康监测. 应对实施挑战是实现其在疾病准备方面充分发挥潜力的关键.
科学领域:
- 传染病诊断 传染病诊断 传染病诊断
- 全球卫生监测全球卫生监测
- 医疗技术创新 医疗技术创新
背景情况:
- 全球POC诊断市场正在迅速扩大,预计到2033年将达到近1000亿美元.
- 传染病分析是主要的市场驱动力,由分子放大,生物传感器,微流体和人工智能的进步推动.
- POC诊断对于将病床检测与人口层面监测联系起来至关重要.
研究的目的:
- 审查技术,临床,监管和公共卫生领域的POC传染病诊断现有证据.
- 突出技术创新和监管调整对POC诊断的影响.
- 确定持续的挑战和未来的方向,以实现公平的采用和全球卫生准备.
主要方法:
- 整合来自技术,临床,监管和公共卫生研究的当前证据.
- 对POC诊断市场趋势和增长预测的分析.
- 检查各种诊断平台 (免疫测试,NAAT,基于CRISPR) 和AI在POC环境中的作用.
- 对监管框架 (FDA,IVDR,WHO) 和验证要求 (CLIA) 的审查.
主要成果:
- 免疫测试被广泛使用,而NAAT和CRISPR平台为POC提供了实验室级敏感性.
- 人工智能越来越多地用于增强图像解释,信号解卷和质量控制.
- POC诊断已经改善了主要传染病 (HIV,结核病,COVID-19等) 的早期检测和疫情制. ) 的情况.
- 严格的验证和适应性监管框架对于可靠的分散测试至关重要.
- 在标准化,报销以及来自低收入和中等收入国家的数据方面仍然存在挑战.
结论:
- POC传染病诊断处于数字化和监管成熟度的关键阶段.
- 解决验证,生命周期监测和实施公平性的差距对于广泛采用至关重要.
- 这些技术作为临床加速器和全球传染病准备的基石具有重大前景.
相关概念视频
Issues And Trends In Healthcare Delivery System
6.1K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.1K
Microorganisms in Medicine and Therapeutics
920
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
920
Enzyme-Linked Immunosorbent Assay
17.2K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
17.2K


